Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations
L Dresser, R Wlodarski, K Rezania… - Journal of clinical medicine, 2021 - mdpi.com
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective
transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases …
transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases …
The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis
PM Rodríguez Cruz, J Cossins, D Beeson… - Frontiers in molecular …, 2020 - frontiersin.org
The neuromuscular junction (NMJ) is a highly specialized synapse between a motor neuron
nerve terminal and its muscle fiber that are responsible for converting electrical impulses …
nerve terminal and its muscle fiber that are responsible for converting electrical impulses …
Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics
K Lazaridis, SJ Tzartos - Frontiers in immunology, 2020 - frontiersin.org
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and
fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by …
fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by …
Seronegative autoimmune diseases: A challenging diagnosis
Autoimmune diseases (AID) are increasingly prevalent conditions which comprise more
than 100 distinct clinical entities that are responsible for a great disease burden worldwide …
than 100 distinct clinical entities that are responsible for a great disease burden worldwide …
Myasthenia gravis—autoantibody characteristics and their implications for therapy
NE Gilhus, GO Skeie, F Romi, K Lazaridis… - Nature reviews …, 2016 - nature.com
Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies that target the
neuromuscular junction, leading to muscle weakness and fatigability. Currently available …
neuromuscular junction, leading to muscle weakness and fatigability. Currently available …
Neuromuscular junction dysfunction in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by
progressive degeneration of motor neurons leading to skeletal muscle denervation. Earlier …
progressive degeneration of motor neurons leading to skeletal muscle denervation. Earlier …
Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture
I Koneczny, R Herbst - Cells, 2019 - mdpi.com
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ).
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …
Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology
ML Fichtner, R Jiang, A Bourke, RJ Nowak… - Frontiers in …, 2020 - frontiersin.org
Myasthenia gravis (MG) is a prototypical autoantibody mediated disease. The
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …
Myasthenia gravis: autoantibody specificities and their role in MG management
K Lazaridis, SJ Tzartos - Frontiers in neurology, 2020 - frontiersin.org
Myasthenia gravis (MG) is the most common autoimmune disorder affecting the
neuromuscular junction, characterized by skeletal muscle weakness and fatigability. It is …
neuromuscular junction, characterized by skeletal muscle weakness and fatigability. It is …
Inflammation, Immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology
MS Lyon, M Wosiski‐Kuhn, R Gillespie… - Muscle & …, 2019 - Wiley Online Library
Amyotrophic lateral sclerosis (ALS) is a severely debilitating disease characterized by
progressive degeneration of motor neurons. Charcot first described ALS in 18691; however …
progressive degeneration of motor neurons. Charcot first described ALS in 18691; however …